 There was extensive pharmacokinetic variability of commonly used AEDs, valproate, lamotrigine and levetiracetam, in and between 80 patients with JME.
Introduction
Patients with juvenile myoclonic epilepsy (JME) may experience challenges in the treatment with antiepileptic drugs (AEDs) when it comes to self-initiated withdrawal, adverse effects and impulsive decision making that may affect adherence (Wanderschneider et al., 2012 , Zamarian et al., 2013 , Syvertsen et al., 2019a . JME is a generalized epilepsy and the most common epilepsy type affecting adolescents. It is characterized by myoclonic jerks, predominantly after awakening, aggravated by sleep deprivation and stress (Kasteleijn-Nolst , Syvertsen et al., 2017 . The majority of patients experience occasional generalized tonic-clonic seizures (GTCS), and about one third have absence seizures (Genton et al., 2013) . Patients with JME often use AEDs for their whole life (Janz, 1989 , Panayiotopoulos et al., 1994 . This may imply a long-term burden of AEDs with a range of adverse effects that may affect adherence and quality of life.
AEDs exhibit extensive pharmacokinetic variability, and most of the drugs are susceptible to be involved in pharmacokinetic interactions (Johannessen Landmark et al., 2012 , Johannessen Landmark and Patsalos, 2010 . According to the most recent updates on evidence-based guidelines, valproate, lamotrigine and levetiracetam are the main AEDs used in generalized epilepsies (Nunes et al., 2012 , Glauser et al., 2013 . The recent restrictions and ban of the use of valproate in women now need careful considerations (EMA, 2018) , due to dose-dependent teratogenic effects and long-term effects on cognitive development on one hand, and safety risks of uncontrolled generalized seizures and risk of maternal death on the other (Edey et al., 2014 , Tomson 2015 , Christensen et al., 2018 . Equally effective AEDs as valproate to treat generalized epilepsies may be difficult to find.
Therapeutic drug monitoring (TDM) is a means to adjust for pharmacokinetic variability, to control for variable adherence and to serve as a quality assurance of the treatment (Johannessen Landmark et al., 2012 , WHO, 2003 , Samsonsen et al., 2015 and has a long tradition as part of a comprehensive care approach in epilepsy in Norway. We have shown pronounced pharmacokinetic variability among women using valproate and how TDM may be used to elucidate variability (Johannessen Landmark et al., 2017 . A recent study from an extended study population demonstrated that 40% of patients with JME had withdrawn AEDs, the majority against medical advice (Syvertsen et al., 2019b) . Close monitoring of the treatment may therefore be of special importance for these patients.
The purpose of the present study was to investigate how the treatment of patients with JME is monitored, to demonstrate pharmacokinetic variability within and between patients by a longterm TDM approach and how this may be used as part of the clinical follow-up.
Methods

Patients, data material and calculations
The patients were recruited from Drammen Hospital during 2016-2018. Drammen Hospital serves all patients with epilepsy in Buskerud County, comprising 9% of Norway's total population. All the included patients had a confirmed JME diagnosis and were aged 14-40 years, as described in detail by Syvertsen et al. (2017 Syvertsen et al. ( , 2019a . Routine TDM data were collected retrospectively from the database at the Section for Clinical Pharmacology, National Center for Epilepsy, Oslo University Hospital and from medical records at Drammen Hospital. To study long-term monitoring in patients, data from January 2007 to April 2018 were used. Measurements of AEDs at assumed steady-state conditions were included, based on blood samples that were drawn drug-fasting in the morning as a standard procedure.
Serum concentrations, doses and concentration/dose (C/D) ratios were calculated as means/medians with standard deviation (SD)/ minimum-maximum range to demonstrate variability. As an expression of pharmacokinetic variability, the value of C/D-ratio maximum/minimum was used, as previously described (Johannessen Landmark et al., 2017 . To assess to what extent lamotrigine was affected by concomitant use of valproate, the mean C/D ratios were compared at the last visit available of those who used the combination versus those who used lamotrigine in monotherapy or with other AEDs without enzyme inhibiting properties. Measurements at pregnancy or where the use of enzyme inducing oral contraceptives were used were excluded.
Long-term TDM data were used to express intra-and interpatient variability, by use of C/Dratios for individual patients with multiple measurements (at least three measurements) and between individuals. The coefficient of variation (CV) between patients were calculated based on Conway et al. (2017) , as the % of the mean C/D ratio/SD x 100 for the three most commonly used drugs, valproate, lamotrigine and levetiracetam. The median value was an expression for intra-patient variability, whereas the range from minimum to maximum value for one drug shows the inter-patient variability between patients in that group. 
Statistical methods
2.3.Ethical considerations
The study was approved by the Regional Committee for Medical Research Ethics, South East Norway (no. 2013/1027) and the data protection officer of Drammen Hospital. Written informed consent was obtained from all participants. Additional consent was given by the patient in the case to elucidate pharmacokinetic variability with long-term TDM.
Results
Patients
Ninety patients were classified with JME. In 80 (88%) TDM measurements had been performed. Mean age was 26 years, and 60% were women. Demographic and clinical characteristics are summarized in Table 1 . Only one third was seizure free the last year, and one fourth had GTCS. Two thirds used monotherapy and 24% used two or three AEDs. There were no significant differences between the 80 patients using AEDs who were included and the ten patients where no serum concentrations were measured, regarding gender and age distribution, seizure debut and type and use of AEDs (data not shown).
Use of therapeutic drug monitoring
Data on use of TDM for nine different AEDs were available. There was a wide variability of the number of serum concentration measurements that had been performed during a period of 10 years, from 1-61; 21 (26%) had at least 10 measurements recorded over the years. The distribution between the two laboratories involved was similar. Measurements from 1-3 AEDs were performed. The most commonly AEDs requested for TDM analysis included lamotrigine, valproate and levetiracetam, as presented in detail (Table 2) .
Pregnancy is an important indication for TDM requests. Data were provided from 13 pregnancies in 10 women, i.e. 20% of the included women. Data from pre-pregnancy throughout all trimesters and post partum were only available in four cases, pointing out incomplete follow-up in the majority of cases. The available data are given in Table 2 , and the corresponding C/D-ratios are marked in Figure 2 .
Pharmacokinetic variability of the most commonly used AEDs
For the three most commonly used AEDs, there was an extensive variability in dose and serum concentration linear relationships both for women and men as illustrated in figure reference range (84%, n=82), while 16% (n=16) were below. In total, in 15% (83/563) serum concentrations were below the reference ranges.
Long-term follow-up with therapeutic drug monitoring
Extensive inter-and intraindividual variability in serum concentration and dose relationships is elucidated in Figure 2 for the three most commonly used drugs in patients with multiple measurements; valproate (a), lamotrigine (b), and levetiracetam (c). Long-term TDM demonstrated variability over time expressed as intra-patient median values and inter-patient ranges of 19% (7-47) for valproate, 43% (10-83) for lamotrigine and 35% (6-111) for levetiracetam ( Table 2 ). The variability between measurements for our patient case described below is shown as #1 in a red box for valproate and lamotrigine. Measurements during pregnancy are marked in Figures 2a,b and c to highlight pregnancy as a cause of variability.
Case description of long-term monitoring in a young woman and clinical implications
This young woman had been followed closely for a period of ten years, and TDM was used as occasions where the serum concentration was below the reference range, Figure 3 ). She underwent one pregnancy in 2014 on valproate and lamotrigine, and this was the only period she was seizure free. Variable adherence, changes in medication, use of an estrogencontaining oral contraceptive and pregnancy all contributed to extensive variability in her dose and serum concentrations, often affecting both drugs (Fig 3) . The misleading use of one serum concentration measurement at a time of low adherence resulted in a dosage increase, followed by a very high serum concentration at the next follow-up. For educational purposes the figure was discussed between the pharmacologists and neurologists, and then with the patient. The discussion contributed to improved understanding of a regular drug intake, and the use of a dosing tool then improved adherence in the following period.
Discussion
In the present study, we demonstrate that TDM is used as part of the follow-up in most patients in a large and well-defined cohort of patients with JME. The pharmacokinetic variability in and between patients is extensive, and the most commonly used and measured AEDs including valproate, lamotrigine and levetiracetam, are described in detail. The majority of patients were not seizure free, and low serum concentrations, below the reference range was common, which could indicate poor adherence. Long-term TDM is used to demonstrate this variability over time. This approach is also demonstrated in a clinical case to
elucidate reasons for variability in a young woman with JME as an example of its clinical application as part of the clinical follow-up to improve our understanding of the treatment.
4.1.The use of antiepileptic drugs and therapeutic drug monitoring in JME
The present study demonstrates that TDM is used in most patients with JME, where the mean number of measurements was six. However, more than 60 measurements were noted in one single patient (the case description). Valproate, lamotrigine and levetiracetam have a longstanding place in the treatment of JME, which is also reflected in the present findings and is in line with another recent study of 240 patients with JME in Portugal (Cacao et al., 2018) . Still, challenges include restrictions in the use of valproate in women of child-bearing potential, possible worsening of myoclonic jerks with lamotrigine, and psychiatric adverse effects seen with levetiracetam. In addition to these drugs, a wide range of different AEDs were used, even if there is a lack of evidence for their use in JME (Nunes et al., 2012 , Glauser et al., 2013 . It is a general problem, that the evidence for choice of AEDs in JME is scarce. The majority of patients were not seizure free, which calls for further evaluation of improvement of their follow-up, like implementation of long-term TDM as elucidated in the clinical case.
4.2.Pharmacokinetic variability
Previous studies have pointed to large variability between patients using valproate, lamotrigine and levetiracetam, and the pronounced enzyme inhibiting effect by valproate on lamotrigine levels (May et al., 2003 , Reimers, 2009 , Johannessen Landmark et al., 2012b , Johannessen Landmark et al., 2017 . Several reasons, like adherence, comedication (with AEDs or other drugs), and patient-related factors may contribute to this (Johannessen Landmark et al., 2012 . JME is associated with frontal lobe dysfunction and impulsivity, which may impair adherence (Moschetta and Valente, 2013 , Wanderschneider et , , Zamarian et al., 2013 . TDM may be a helpful tool in this regard, as it has been considered the most efficient method to control for poor adherence (WHO, 2003) , which may be of major importance in this particular patient group.
There were six patients with serum concentrations of valproate below the reference range, and five who were free from GTCSs during the last year, supporting the clinical experience that even low exposure of valproate may protect against generalized seizures. The mean dose of valproate was lower in women than men, but the serum concentrations were similar. Most women used low doses of valproate as recommended below 700 mg/day, when it comes to lowering the risk of malformations (Tomson et al., 2015) . We discovered incomplete measurements performed during pregnancy in ten women that did not allow for further calculations on C/D ratios, and unbound valproate was not measured. Women should be more closely followed, and valproate should be monitored to a minimum effective exposure based on the use of TDM, as the pharmacokinetic variability is pronounced, and the dosage is a poor approximation of exposure (Johannessen Landmark et al., 2017 . In addition, TDM could help to decrease the risk of uncontrolled seizures in women by maintenance of an optimal individual serum concentration and controlling for poor adherence. The risk of SUDEP is increased in those with uncontrolled generalized seizures, and the risk of maternal death is 10-fold increased in those with uncontrolled generalized seizures during pregnancy (Edey et al., 2014) .
Clinical implications of long-term therapeutic drug monitoring
The clinical implications of closer follow-up of these patients are important, as only one third of the patients were seizure free and 19% have uncontrolled GTCSs during the last year. In a similar study from Portugal, half of the patients were seizure free the last year and 50% were
regarded as being refractory to treatment (Cacao et al., 2018) . In patients followed over time, the approach of long-term TDM may improve the evaluation of pharmacokinetic variability as well as patient-related factors over time, within an individual patient and between patients. It is well known that patients are concerned about adherence, adverse effects and seizure control that affect their quality of life (Mevaag et al., 2017 , Henning et al., 2019 . By collecting all available data for 10 years, we had considerable data to analyze in many of the patients to
give a comprehensive long-term overview of the use of TDM and elucidate intra-patient variability and then compare groups among the patients.
As demonstrated by Conway et al. (2017) the use of CVs indicated that more than one serum concentration measurement may be necessary in a patient to determine a true systemic exposure trend over time. Similarly, in patients with JME using various AEDs, the variability of valproate, lamotrigine and levetiracetam was considerable. Lamotrigine is known to be susceptible to drug interactions by enzyme inducers such as carbamazepine and similar drugs (oxcarbazepine, eslicarbazepine), enzyme inhibitors like valproate, and other drugs, such as oral contraceptives Patsalos, 2010, Johannessen and In the present study, lamotrigine clearly had the most extensive variability within and between patients. Over a period of up to 10 years, often from early adolescent age to adulthood, many changes may happen regarding the therapy and the patients' situation.
Figure 3 was used as a tool to discuss variability, adherence and seizure control with the patient. The visualization of pharmacokinetic variability and use of TDM over a long time gave rise to an interesting discussion with the patient in our case study, pointing to reasons as variable adherence for subtherapeutic serum concentrations and poor seizure control. The application of the long-term TDM data improved our understanding of variability and seizure situation for the patient, neurologist and pharmacologist.
Methodological considerations
Retrospective studies have limitations, but they may be the only option for long-term followup and for pharmacokinetic purposes (Perucca and Wiebe, 2016) . The established practice for TDM in Norway is a standardized blood sampling time, drug fasting before the morning dose at steady-state, but it cannot be assured that this is always correct. We have previously demonstrated that the quality of the information given in the request forms is equally correct to medical records (Svendsen et al., 2017) , and this was also checked in the present study.
Poor adherence cannot be controlled for in a realistic and retrospective setting, also illustrated in the patient case, where wrong decisions may be taken of dosage adjustments based on one misleading measurement.
Conclusions
In conclusion, the present study demonstrates extensive inter-and intra-patient pharmacokinetic variability in patients with JME with long-term TDM follow-up. This points to a need for close follow-up in this group of patients. Serum concentrations in many patients below the reference ranges could correspond to poor adherence, resulting in a poor treatment outcome, as the majority of patients were not seizure free. Inter-and intra-patient variability measures may be used in a clinical setting for educational purposes to increase the understanding of the patient towards variability, adherence and risk of seizures. This approach may contribute to closer monitoring of patients with JME and be used as a practical tool during clinical consultations for improved follow-up. and lamotrigine (red, below), are shown in a young woman with JME over 10 years . The variability is related to external factors like seizure situation, dosage adjustments, poor adherence and pregnancy, often affecting both drugs, as shown with arrows where available from the medical record. Blue illustrates poor adherence, yellow seizure situation, green before and after and orange during pregnancy, and grey colour points to an explanation of a decision of a dose increase based on a single low value. The reference ranges are marked with dotted lines. 53 (67) 16 (20) 2 (2) AEDs=antiepileptic drugs (44) 216 (43) 98 (29) 41 (4) 35 (4) 13 (2) 8 (8) 5 ( 
